Alnylam Pharmaceuticals (ALNY) Cash from Investing Activities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Cash from Investing Activities for 18 consecutive years, with -$363.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Investing Activities fell 157.08% year-over-year to -$363.5 million; the trailing twelve-month figure through Jun 2026 stood at $74.9 million (up 167.65% YoY), and the FY2025 full-year result was $436.3 million, up 473.44% from the prior year.
• Cash from Investing Activities fell to -$363.5 million in Q2 2026 per ALNY's latest filing, from -$25.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $501.1 million in Q3 2025 and bottomed at -$363.5 million in Q2 2026.
• Historically, Cash from Investing Activities has averaged -$13.1 million across 5 years, with a median of -$33.7 million in 2024.
• The widest YoY moves for Cash from Investing Activities: up 1756.55% in 2025, down 516.56% in 2025.
• Over 5 years, Cash from Investing Activities stood at -$139.9 million in 2022, then plunged by 72.01% to -$240.7 million in 2023, then soared by 78.01% to -$52.9 million in 2024, then grew by 29.76% to -$37.2 million in 2025, then slumped by 877.93% to -$363.5 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$363.5 million, -$25.5 million, and -$37.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.